Information Provided By: 
Fly News Breaks for January 24, 2018
ANIK
Jan 24, 2018 | 05:26 EDT
First Analysis analyst Joseph Munda upgraded Anika Therapeutics to Overweight and raised his price target for the shares to $68 from $45. A meeting with management gives the analyst confidence that Anika can effectively commercialize products without having to use DePuy Mitek as a marketing partner. In addition to a "deep product pipeline, this osteoarthritis therapy leader has a strong margin profile," Munda tells investors in a research note.
News For ANIK From the Last 2 Days
There are no results for your query ANIK
